DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.
O que mudou
The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.
Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.
Por que importa
Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.
O que observar
O sinal útil não é só o número da manchete, mas se o produto, contrato ou deslocamento de plataforma se repete nos próximos dois trimestres.
Fontes: CocoLoop